Terns Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Terns Pharmaceuticals, Inc.

Jan-07	Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference TERN GlobeNewswire
Jan-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire
Dec-11	Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares TERN GlobeNewswire
Dec-09	Terns Announces Pricing of Upsized $650 Million Public Offering TERN GlobeNewswire
Dec-09	Terns Announces Proposed Public Offering TERN GlobeNewswire
Dec-08	Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting TERN GlobeNewswire
Nov-14	Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London TERN GlobeNewswire
Nov-10	Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates TERN GlobeNewswire
Nov-04	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire
Nov-03	Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting TERN GlobeNewswire
Oct-21	Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity TERN GlobeNewswire
Oct-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire
Aug-21	Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 TERN GlobeNewswire
Aug-05	Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates TERN GlobeNewswire
Aug-04	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire
Jun-23	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions TERN GlobeNewswire
May-29	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences TERN GlobeNewswire
May-14	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 TERN GlobeNewswire
May-08	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates TERN GlobeNewswire
May-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire

Terns Pharmaceuticals, Inc.

Recent Articles by Terns Pharmaceuticals, Inc.

Upgrade your FINVIZ experience